Andrea Dennis1, Matt D Kelly1, Carolina Fernandes1, Sofia Mouchti1, Jonathan A Fallowfield2, Gideon Hirschfield3, Michael Pavlides4,5,6, Stephen Harrison4,7, Manu V Chakravarthy8, Rajarshi Banerjee1, Arun Sanyal9. 1. Perspectum, Oxford, United Kingdom. 2. Centre for Inflammation Research, University of Edinburgh, Edinburgh, United Kingdom. 3. Toronto Centre for Liver Disease, University Health Network, Toronto, ON, Canada. 4. Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom. 5. Translational Gastroenterology Unit, University of Oxford, Oxford, United Kingdom. 6. Oxford NIHR Biomedical Research Centre, University of Oxford, Oxford, United Kingdom. 7. Pinnacle Clinical Research, San Antonio, TX, United States. 8. Axcella Health, Cambridge, MA, United States. 9. Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, United States.
Abstract
Introduction: Late stage clinical trials in non-alcoholic steatohepatitis (NASH) are currently required by the FDA to use liver biopsy as a primary endpoint. The well-reported limitations with biopsy, such as associated risks and sampling error, coupled with patient preference, are driving investigation into non-invasive alternatives. MRI-derived biomarkers proton density fat fraction (PDFF) and iron-corrected T1 mapping (cT1) are gaining traction as emerging alternatives to biopsy for NASH. Our aim was to explore the correlations between cT1 and PDFF (from LiverMultiScan®), with the histological components on the NAFLD-NASH spectrum in a large cohort of cross-sectional data, in order to calibrate the measurement to histology, and to infer what might constitute a clinically meaningful change when related to the FDA's criteria. Materials and Methods: In a retrospective analysis of data combined from three previously published observational NASH studies, in which adult participants who underwent liver biopsy on suspicion of NAFLD or NASH and had an MRI scan measuring cT1 and PDFF (LiverMultiScan®, Perspectum Ltd, UK), associations between imaging biomarkers and histology were tested using Spearman's rank correlation coefficient (rs), and further exploration of the relationships between the imaging variables and histology were performed using linear regression. Results: N = 264 patients with mean age of 54 (SD:9.9), 39% female, and 69% with BMI ≥ 30kg.m-2 were included in the analysis. cT1 and PDFF both correlated with all features of the NAFLD activity score (NAS). cT1 was also positively correlated with Kleiner-Brunt fibrosis. Partial correlations, adjusting for steatosis, revealed cT1 correlated with inflammation and fibrosis, whereas PDFF did not, and both were still associated with the NAS, but correlation was weaker with PDFF than cT1. An estimated difference of 88 ms in cT1, or 21% relative difference in PDFF was related to a two-point difference in overall NAS. Conclusion: The correlations between cT1 and PDFF with the histopathological hallmarks of NASH demonstrate the potential utility of both cT1 and PDFF as non-invasive biomarkers to detect a pharmacodynamic change in NASH, with cT1 showing superiority for detecting changes in inflammation and fibrosis, rather than liver fat alone.
Introduction: Late stage clinical trials in non-alcoholic steatohepatitis (NASH) are currently required by the FDA to use liver biopsy as a primary endpoint. The well-reported limitations with biopsy, such as associated risks and sampling error, coupled with patient preference, are driving investigation into non-invasive alternatives. MRI-derived biomarkers proton density fat fraction (PDFF) and iron-corrected T1 mapping (cT1) are gaining traction as emerging alternatives to biopsy for NASH. Our aim was to explore the correlations between cT1 and PDFF (from LiverMultiScan®), with the histological components on the NAFLD-NASH spectrum in a large cohort of cross-sectional data, in order to calibrate the measurement to histology, and to infer what might constitute a clinically meaningful change when related to the FDA's criteria. Materials and Methods: In a retrospective analysis of data combined from three previously published observational NASH studies, in which adult participants who underwent liver biopsy on suspicion of NAFLD or NASH and had an MRI scan measuring cT1 and PDFF (LiverMultiScan®, Perspectum Ltd, UK), associations between imaging biomarkers and histology were tested using Spearman's rank correlation coefficient (rs), and further exploration of the relationships between the imaging variables and histology were performed using linear regression. Results: N = 264 patients with mean age of 54 (SD:9.9), 39% female, and 69% with BMI ≥ 30kg.m-2 were included in the analysis. cT1 and PDFF both correlated with all features of the NAFLD activity score (NAS). cT1 was also positively correlated with Kleiner-Brunt fibrosis. Partial correlations, adjusting for steatosis, revealed cT1 correlated with inflammation and fibrosis, whereas PDFF did not, and both were still associated with the NAS, but correlation was weaker with PDFF than cT1. An estimated difference of 88 ms in cT1, or 21% relative difference in PDFF was related to a two-point difference in overall NAS. Conclusion: The correlations between cT1 and PDFF with the histopathological hallmarks of NASH demonstrate the potential utility of both cT1 and PDFF as non-invasive biomarkers to detect a pharmacodynamic change in NASH, with cT1 showing superiority for detecting changes in inflammation and fibrosis, rather than liver fat alone.
Authors: Mustafa R Bashir; Tanya Wolfson; Anthony C Gamst; Kathryn J Fowler; Michael Ohliger; Shetal N Shah; Adina Alazraki; Andrew T Trout; Cynthia Behling; Daniela S Allende; Rohit Loomba; Arun Sanyal; Jeffrey Schwimmer; Joel E Lavine; Wei Shen; James Tonascia; Mark L Van Natta; Adrija Mamidipalli; Jonathan Hooker; Kris V Kowdley; Michael S Middleton; Claude B Sirlin Journal: J Magn Reson Imaging Date: 2018-10-14 Impact factor: 4.813
Authors: Stephen A Harrison; Mustafa R Bashir; Cynthia D Guy; Rong Zhou; Cynthia A Moylan; Juan P Frias; Naim Alkhouri; Meena B Bansal; Seth Baum; Brent A Neuschwander-Tetri; Rebecca Taub; Sam E Moussa Journal: Lancet Date: 2019-11-11 Impact factor: 79.321
Authors: Elizabeth M Tunnicliffe; Rajarshi Banerjee; Michael Pavlides; Stefan Neubauer; Matthew D Robson Journal: J Magn Reson Imaging Date: 2016-07-23 Impact factor: 4.813
Authors: Stephen A Harrison; Andrea Dennis; Martine M Fiore; Matt D Kelly; Catherine J Kelly; Angelo H Paredes; Jennifer M Whitehead; Stefan Neubauer; Peter G Traber; Rajarshi Banerjee Journal: PLoS One Date: 2018-09-07 Impact factor: 3.240
Authors: Rajarshi Banerjee; Michael Pavlides; Elizabeth M Tunnicliffe; Stefan K Piechnik; Nikita Sarania; Rachel Philips; Jane D Collier; Jonathan C Booth; Jurgen E Schneider; Lai Mun Wang; David W Delaney; Ken A Fleming; Matthew D Robson; Eleanor Barnes; Stefan Neubauer Journal: J Hepatol Date: 2013-09-12 Impact factor: 25.083
Authors: Natasha McDonald; Peter J Eddowes; James Hodson; Scott I K Semple; Nigel P Davies; Catherine J Kelly; Stella Kin; Miranda Phillips; Amy H Herlihy; Timothy J Kendall; Rachel M Brown; Desley A H Neil; Stefan G Hübscher; Gideon M Hirschfield; Jonathan A Fallowfield Journal: Sci Rep Date: 2018-06-15 Impact factor: 4.379
Authors: A Mojtahed; C J Kelly; A H Herlihy; S Kin; H R Wilman; A McKay; M Kelly; M Milanesi; S Neubauer; E L Thomas; J D Bell; R Banerjee; M Harisinghani Journal: Abdom Radiol (NY) Date: 2019-01
Authors: Mark Barahman; Eduardo Grunvald; Pablo J Prado; Alejandro Bussandri; Walter C Henderson; Tanya Wolfson; Kathryn J Fowler; Claude B Sirlin Journal: Magn Reson Med Date: 2022-05-25 Impact factor: 3.737
Authors: Stephen A Harrison; Seth J Baum; Nadege T Gunn; Ziad H Younes; Anita Kohli; Rashmee Patil; Margaret J Koziel; Harinder Chera; Jeff Zhao; Manu V Chakravarthy Journal: Am J Gastroenterol Date: 2021-12-01 Impact factor: 12.045
Authors: Hykoush A Asaturyan; Nicolas Basty; Marjola Thanaj; Brandon Whitcher; E Louise Thomas; Jimmy D Bell Journal: PLoS One Date: 2022-09-13 Impact factor: 3.752